As per the 2017 American College of Cardiology and American Heart Association guidelines, a blood pressure 130/80 mmHg is considered as hypertension. Ambulatory Blood Pressure Monitoring (ABPM) provides automated measurements of blood pressure over a 24-hour period while patients are engaging in their usual activities. Angiotensin Receptor Blockers (ARBs) inhibit the action of angiotensin II by binding directly to angiotensin 1 receptor and are most tolerated. Various studies have evaluated the efficacy and safety profile of Azilsartan medoxomil (AZL-M) and Telmisartan (TEL) in comparison to other ARBs or Angiotensin Converting Enzyme Inhibitors. Aim of this study was evaluate the efficacy and safety of Azilsartan medoxomil versus Telmisartan using Ambulatory Blood Pressure Monitoring, in approved doses.